Kamada Ltd (KMDA) Stock Analysis and Metrics

Kamada

NASDAQ: KMDA

$7.03 ▲ +0.07 (+0.93%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap405.83 Mn

P/E23.37

P/S0.01

Div. Yield0.00

ROIC (Qtr)5.77

Total Debt (Qtr)10.64 Mn

Revenue Growth (1y) (Qtr)2.78

Add ratio to table…

About

Kamada Ltd is a global biopharmaceutical company focused on the development, manufacture, and commercialization of specialty plasma derived therapies for rare and serious conditions. The company operates in the biopharmaceutical industry leveraging its proprietary technology platform to extract and purify immunoglobulins from human plasma. Kamada Ltd markets its own portfolio of FDA approved products and also distributes third party pharmaceutical products in Israel through licensing agreements. It has a presence in more than 30 countries worldwide including the United States, Israel, Canada, Europe and Latin America. The company maintains a cGMP manufacturing facility in Beit Kama, Israel and operates three plasma collection centers in the United States located in Beaumont, Houston and San Antonio. The company also invests in research and development of new product candidates targeting unmet medical needs, including inhaled and recombinant alpha 1 antitrypsin therapies.

The company generates revenue primarily from sales of its proprietary products, which include KEDRAB, GLASSIA, CYTOGAM, WINRHO SDF, VARIZIG, HEPAGAM B, KAMRAB and equine based antivenom products. In 2025 the Proprietary Products segment generated $156.2 million in sales, compared to $141.4 million in 2024 and $115.5 million in 2023. Additional revenue streams consist of royalty income from licensing agreements such as the $15.8 million received from Takeda for GLASSIA in 2025 and sales of normal source plasma collected from its U. S plasma collection centers. Under the Takeda licensing agreement Kamada Ltd is entitled to a guaranteed minimum of $5 million in annual royalty income through 2040. The Distribution segment contributes revenue through the sale of licensed third party pharmaceuticals, including biosimilar products, to healthcare providers in Israel, generating $24.3 million in 2025 versus $19.5 million in 2024 and $27.1 million in 2023.

The company operates through the following segments: the Proprietary Products segment and the Distribution segment.

• Proprietary Products segment: This segment encompasses the company's portfolio of specialty plasma derived therapies, including six FDA approved products such as KEDRAB for rabies prophylaxis, GLASSIA for alpha 1 antitrypsin deficiency, CYTOGAM for cytomegalovirus prevention, WINRHO SDF for immune thrombocytopenic purpura, VARIZIG for varicella zoster prophylaxis, and HEPAGAM B for hepatitis B prevention, as well as KAMRAB and equine based antivenom products. It also includes plasma collection operations in the United States that collect hyper immune plasma for internal use and normal source plasma for sale to third parties, and manufacturing conducted at its cGMP facility in Beit Kama, Israel and via contract manufacturers. The segment reported sales of $156.2 million in 2025, $141.4 million in 2024 and $115.5 million in 2023, with the majority of revenue derived from sales in the United States. The company expects each of its Houston and San Antonio plasma collection centers to generate between $8 million and $10 million annually in normal source plasma sales once fully operational.

• Distribution segment: This segment focuses on the commercialization and distribution of licensed third party pharmaceutical products in Israel, including more than 25 products such as biosimilars like BEVACIZUMAB KAMADA and PEGFILGRASTIM KAMADA, as well as therapeutics for respiratory, inflammatory, oncology, and other therapeutic areas. The segment leverages Kamada Ltd's local market expertise to register, promote, and sell these products to Israeli health maintenance organizations, hospitals, and pharmacies. In 2025 the Distribution segment generated $24.3 million in sales, up from $19.5 million in 2024 and $27.1 million in 2023, driven by the launch of two biosimilar products and increased demand for existing portfolio items. The segment is also expanding its distribution network into the Middle East and North Africa region by partnering with local pharmaceutical companies to register and sell its licensed products.

Kamada Ltd holds a leading position in the niche market of specialty plasma derived therapies, competing with larger plasma product manufacturers such as CSL Behring, Grifols, and Kedrion. The company's competitive advantages stem from its proprietary plasma fractionation technology, integrated plasma collection capabilities, strategic partnerships with firms like Kedrion and Takeda, and a portfolio of orphan designated products that provide market exclusivity. Its ability to develop and commercialize both plasma derived and licensed products allows it to address a broad range of rare diseases while maintaining flexibility in sourcing and manufacturing. The company also benefits from orphan drug designations in the United States and the European Union for several of its products, which help secure market protection and support premium pricing. In the United States the company faces competition from Grifols' Prolastin for alpha 1 antitrypsin deficiency and from CSL Behring's Zemaira, while its rabies immunoglobulin product competes mainly with Grifols' offerings.

Kamada Ltd's customer base includes hospitals, clinics, health maintenance organizations, and government agencies worldwide. Key customers comprise Kedrion, which distributes KEDRAB in the United States; Takeda, which pays royalties on GLASSIA sales in North America; Clalit Health Services and Maccabi Healthcare Services, major Israeli health maintenance organizations; the Israeli Ministry of Health (IMOH); and various U. S wholesalers such as McKesson. Internationally, the company sells to distributors in Argentina, Russia, the Middle East and North Africa region, and other territories, as well as to international organizations that procure its products for global health initiatives. The company also supplies its products to an international organization that serves as a regional office for the World Health Organization for distribution in Latin America. Additional customers include various U. S based wholesalers, an international organization, and distributors in countries such as Turkey, South Korea and Australia.

Investment Thesis

▲ Bull case

Kamada's Kedrion partnership represents a highly underappreciated growth engine, as the company indicated that actual KEDRAB supply will exceed the $90 million minimum commitment through 2027, with the agreement running through 2031 providing long-term revenue visibility; this commitment alone implies steady high-margin specialty plasma product demand, yet the market appears to be pricing the stock as if this is a finite or capped opportunity rather than a scalable foundation for organic expansion, especially given increasing end-user utilization in the U.S. and international markets like Canada, Latin America, Australia, and Israel, which management cited as growing significantly and supporting confidence in stronger full-year results despite the Q1 shipment delay.
The plasma collection vertical integration initiative is poised to become a material profit driver sooner than anticipated, with FDA approval of the San Antonio center already secured and normal source plasma sales expected to initiate in the second half of 2026, yet the market may be overlooking that each Houston and San Antonio center is projected to generate $8 million to $10 million annually at full capacity, and while full capacity is targeted for late 2027 to early 2028, the ramp-up phase alone could contribute meaningfully to 2026 adjusted EBITDA, which management reiterated at $50 million to $53 million for the year based solely on organic growth, implying that plasma-derived revenue streams are already being factored into guidance despite minimal investor focus on this segment's near-term inflection.
Biosimilars expansion in Israel and the MENA region presents a stealthy catalyst for distribution segment growth, with five biosimilar products expected to be on the Israeli market by year-end and an annual sales target of $15 million to $20 million within 4-5 years, yet the market appears to be underestimating the speed and scalability of this rollout, as Kamada already has three products launched, two more imminent within weeks, and is actively signing distribution agreements in MENA with plans to launch products in the second half of 2026 into 2027, suggesting that the distribution portfolio—already comprising ~40 products and targeting 45 by end-2026—could deliver faster-than-expected top-line contribution, particularly as management noted Q1 distribution sales growth was broad-based across the portfolio, not driven by any single product, indicating healthy underlying demand and successful commercial execution.
The company's capital allocation strategy, particularly its commitment to distributing at least 50% of annual net income as dividends—evidenced by the Q1 $0.25 per share payout totaling $14.4 million—combined with a growing cash balance of $73.1 million, signals financial discipline and shareholder return focus that the market may be undervaluing, especially since this policy is paired with active M&A and business development efforts described as ongoing and aimed at securing complementary transactions that would generate synergies with the existing portfolio, suggesting that Kamada is not only generating sustainable free cash flow but also has the liquidity and intent to pursue accretive growth opportunities without relying on external financing, a trait often rewarded in specialty pharma but potentially overlooked amid focus on near-term gross margin fluctuations.

Kamada's Kedrion partnership represents a highly underappreciated growth engine, as the company indicated that actual KEDRAB supply will exceed the $90 million minimum commitment through 2027, with the agreement running through 2031 providing long-term revenue visibility; this commitment alone implies steady high-margin specialty plasma product demand, yet the market appears to be pricing the stock as if this is a finite or capped opportunity rather than a scalable foundation for organic expansion, especially given increasing end-user utilization in the U.S. and international markets like Canada, Latin America, Australia, and Israel, which management cited as growing significantly and supporting confidence in stronger full-year results despite the Q1 shipment delay.
The plasma collection vertical integration initiative is poised to become a material profit driver sooner than anticipated, with FDA approval of the San Antonio center already secured and normal source plasma sales expected to initiate in the second half of 2026, yet the market may be overlooking that each Houston and San Antonio center is projected to generate $8 million to $10 million annually at full capacity, and while full capacity is targeted for late 2027 to early 2028, the ramp-up phase alone could contribute meaningfully to 2026 adjusted EBITDA, which management reiterated at $50 million to $53 million for the year based solely on organic growth, implying that plasma-derived revenue streams are already being factored into guidance despite minimal investor focus on this segment's near-term inflection.
Biosimilars expansion in Israel and the MENA region presents a stealthy catalyst for distribution segment growth, with five biosimilar products expected to be on the Israeli market by year-end and an annual sales target of $15 million to $20 million within 4-5 years, yet the market appears to be underestimating the speed and scalability of this rollout, as Kamada already has three products launched, two more imminent within weeks, and is actively signing distribution agreements in MENA with plans to launch products in the second half of 2026 into 2027, suggesting that the distribution portfolio—already comprising ~40 products and targeting 45 by end-2026—could deliver faster-than-expected top-line contribution, particularly as management noted Q1 distribution sales growth was broad-based across the portfolio, not driven by any single product, indicating healthy underlying demand and successful commercial execution.
The company's capital allocation strategy, particularly its commitment to distributing at least 50% of annual net income as dividends—evidenced by the Q1 $0.25 per share payout totaling $14.4 million—combined with a growing cash balance of $73.1 million, signals financial discipline and shareholder return focus that the market may be undervaluing, especially since this policy is paired with active M&A and business development efforts described as ongoing and aimed at securing complementary transactions that would generate synergies with the existing portfolio, suggesting that Kamada is not only generating sustainable free cash flow but also has the liquidity and intent to pursue accretive growth opportunities without relying on external financing, a trait often rewarded in specialty pharma but potentially overlooked amid focus on near-term gross margin fluctuations.

▼ Bear case

The gross margin contraction to 42% from 47% in Q1 FY26, explicitly attributed by management to an unfavorable product and market sales mix, may signal deeper structural challenges in product portfolio profitability that are being masked by top-line growth narratives, particularly as the decline coincided with reduced R&D spending following the InnovAATe trial termination—a move that lowers expenses but raises concerns about long-term pipeline replenishment—and while management framed the mix shift as temporary, the persistence of such margin pressure could indicate weakening demand for higher-margin specialty products like CYTOGAM or GLASSIA relative to lower-margin distribution or plasma sales, a shift that, if sustained, would undermine the scalability of adjusted EBITDA growth toward the guided $50 million to $53 million range despite revenue increases.
Although Kamada reiterated 2026 guidance of $200 million to $205 million in revenue and $50 million to $53 million in adjusted EBITDA based solely on organic growth, the guidance implies only 12% revenue and 23% EBITDA growth at midpoints versus 2025 results, which may be overly optimistic given the Q1 revenue increase was just 3% year-over-year and driven partly by a $2.4 million shipment delay reversal in April—meaning organic Q1 growth was likely flat or negative—and with plasma center sales not expected to meaningfully contribute until H2 2026 and biosimilars still in early launch phases, the market may be ignoring the risk that second-half execution must accelerate dramatically to meet full-year targets, especially considering the company’s history of shipment disruptions due to geopolitical factors like limited Middle East flights, which could recur and again defer revenue recognition.
The expansion into normal source plasma sales, while framed as a vertical integration advantage, carries execution and market risks that are underdiscussed, including the need to build donor pipelines, achieve regulatory compliance across multiple jurisdictions (including potential EMA inspection for Houston and San Antonio centers), and compete in a commoditized plasma market where pricing pressure could limit the $8 million to $10 million annual revenue potential per center, yet Kamada’s commentary assumes smooth ramp-up to full capacity by late 2027 to early 2028 without addressing potential donor acquisition challenges, seasonal variability in plasma collection, or the capital intensity of maintaining three centers (Beaumont, Houston, San Antonio), which could divert focus and funds from higher-margin specialty products if plasma margins fail to meet expectations.
Despite optimistic commentary on CYTOGAM’s post-marketing research program—including the SHIELD study and UCSF lung transplant data—there is no evidence of imminent label expansion or guaranteed reimbursement uptake, and the product remains dependent on niche transplant populations; the market may be ignoring that CMV prophylaxis in high-risk recipients is already addressed by antivirals, and while immune modulation data is scientifically intriguing, translating such findings into widespread clinical adoption requires costly, lengthy outcomes studies and payer buy-in, meaning that increased product utilization, as hoped by management, is far from assured and could remain constrained by standard-of-care inertia, leaving CYTOGAM’s growth potential as a speculative catalyst rather than a near-term driver, especially amid reduced R&D spend post-InnovAATe termination which limits agility in responding to clinical data gaps.

The gross margin contraction to 42% from 47% in Q1 FY26, explicitly attributed by management to an unfavorable product and market sales mix, may signal deeper structural challenges in product portfolio profitability that are being masked by top-line growth narratives, particularly as the decline coincided with reduced R&D spending following the InnovAATe trial termination—a move that lowers expenses but raises concerns about long-term pipeline replenishment—and while management framed the mix shift as temporary, the persistence of such margin pressure could indicate weakening demand for higher-margin specialty products like CYTOGAM or GLASSIA relative to lower-margin distribution or plasma sales, a shift that, if sustained, would undermine the scalability of adjusted EBITDA growth toward the guided $50 million to $53 million range despite revenue increases.
Although Kamada reiterated 2026 guidance of $200 million to $205 million in revenue and $50 million to $53 million in adjusted EBITDA based solely on organic growth, the guidance implies only 12% revenue and 23% EBITDA growth at midpoints versus 2025 results, which may be overly optimistic given the Q1 revenue increase was just 3% year-over-year and driven partly by a $2.4 million shipment delay reversal in April—meaning organic Q1 growth was likely flat or negative—and with plasma center sales not expected to meaningfully contribute until H2 2026 and biosimilars still in early launch phases, the market may be ignoring the risk that second-half execution must accelerate dramatically to meet full-year targets, especially considering the company’s history of shipment disruptions due to geopolitical factors like limited Middle East flights, which could recur and again defer revenue recognition.
The expansion into normal source plasma sales, while framed as a vertical integration advantage, carries execution and market risks that are underdiscussed, including the need to build donor pipelines, achieve regulatory compliance across multiple jurisdictions (including potential EMA inspection for Houston and San Antonio centers), and compete in a commoditized plasma market where pricing pressure could limit the $8 million to $10 million annual revenue potential per center, yet Kamada’s commentary assumes smooth ramp-up to full capacity by late 2027 to early 2028 without addressing potential donor acquisition challenges, seasonal variability in plasma collection, or the capital intensity of maintaining three centers (Beaumont, Houston, San Antonio), which could divert focus and funds from higher-margin specialty products if plasma margins fail to meet expectations.
Despite optimistic commentary on CYTOGAM’s post-marketing research program—including the SHIELD study and UCSF lung transplant data—there is no evidence of imminent label expansion or guaranteed reimbursement uptake, and the product remains dependent on niche transplant populations; the market may be ignoring that CMV prophylaxis in high-risk recipients is already addressed by antivirals, and while immune modulation data is scientifically intriguing, translating such findings into widespread clinical adoption requires costly, lengthy outcomes studies and payer buy-in, meaning that increased product utilization, as hoped by management, is far from assured and could remain constrained by standard-of-care inertia, leaving CYTOGAM’s growth potential as a speculative catalyst rather than a near-term driver, especially amid reduced R&D spend post-InnovAATe termination which limits agility in responding to clinical data gaps.

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Geographical areas [axis] Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical areas [axis] Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password